Skip to main content
20th November 2026

Exeter College Fellow contributes to new research tackling antibiotic resistance

Exeter College Monsanto Senior Research Fellow, Dr Georgia Isom, has co-led new research revealing a promising approach to tackling antibiotic resistance by encouraging bacteria to destroy the enzymes that protect them from antibiotics. 

The research, published in Angewandte Chemie International Edition,  was co-led by Dr Isom and Professor Thomas Lanyon-Hogg from Oxford’s Department of Pharmacology. The experimental work was primarily carried out by DPhil student Emilia Taylor, who was jointly supervised by both researchers. 

Antimicrobial resistance is a major global health challenge, with one in six bacterial infections now resistant to antibiotic treatments. Developing new antibiotics is difficult, making it increasingly important to find ways to preserve the effectiveness of existing drugs. 

The study investigated a new approach using ‘molecular glues’ to target enzymes called β-lactamases, which allow bacteria to resist widely used antibiotics, including penicillin. 

Rather than simply blocking these enzymes, the molecular glues redirect the bacteria’s own protein-degrading machinery to break them down. 

The researchers developed a compound called OXF-232, which significantly increased the breakdown of resistance-causing enzymes in laboratory experiments. When tested against a highly resistant strain of E. coli, the compound enhanced the effectiveness of the antibiotic piperacillin and, under certain conditions, outperformed an existing treatment. 

Dr Isom, who is also a Group Leader at the Sir William Dunn School of Pathology, said:  

Rather than following the traditional approach of developing drugs to block the function of bacterial resistance enzymes, our molecular glues can essentially chemically reprogram the bacterial cell to destroy its own resistance mechanism. 

The findings offer a potential new strategy for combating antibiotic resistance and could help extend the effectiveness of existing treatments. 

Share this article